diclofenac has been researched along with Cystic Fibrosis of Pancreas in 2 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "60% diclofenac was released within 3 h and 80% tobramycin was released within 45 min." | 5.72 | Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles. ( Hosseini, M; Marasini, N; Sheikh, Z; Spicer, PT; Traini, D; Wong, CYJ; Xin Ong, H; Young, P, 2022) |
| "60% diclofenac was released within 3 h and 80% tobramycin was released within 45 min." | 1.72 | Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles. ( Hosseini, M; Marasini, N; Sheikh, Z; Spicer, PT; Traini, D; Wong, CYJ; Xin Ong, H; Young, P, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marasini, N | 1 |
| Sheikh, Z | 2 |
| Wong, CYJ | 1 |
| Hosseini, M | 1 |
| Spicer, PT | 1 |
| Young, P | 1 |
| Xin Ong, H | 1 |
| Traini, D | 2 |
| Gomes Dos Reis, L | 1 |
| Bradbury, P | 1 |
| Meneguzzo, G | 1 |
| Scalia, S | 1 |
| Young, PM | 1 |
| Ong, HX | 1 |
2 other studies available for diclofenac and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles.
Topics: Administration, Inhalation; Cystic Fibrosis; Diclofenac; Dry Powder Inhalers; Excipients; Humans; Pa | 2022 |
Development and in vitro characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis.
Topics: Administration, Inhalation; Anti-Inflammatory Agents; Bronchodilator Agents; Cystic Fibrosis; Diclof | 2021 |